Business Context and Reporting Period
Organon & Co. filed a Form 8-K reporting the results of its 2024 Annual Meeting of Shareholders held on June 4, 2024. The report was signed and dated June 6, 2024.
Of 257,172,661 outstanding shares entitled to vote, 221,544,166 shares were represented, or approximately 86%.
Financial and Operating Metrics
This filing concerns corporate governance matters and does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating-financial metrics.
Material Changes Versus the Prior Comparable Period
The filing does not provide a comparable-period financial analysis or identify material changes in operating or financial performance.
Meeting Results, Outlook, and Risks
| Proposal | Result | Key vote |
|---|---|---|
| Election of four Class III directors | All nominees elected to serve until the 2025 annual meeting or until successors are elected and qualified. | Votes in favor ranged from 173,247,544 to 176,343,603; each nominee received 42,633,186 broker non-votes. |
| Advisory approval of named executive officer compensation | Approved on a non-binding advisory basis. | 149,712,445 for; 28,201,528 against; 997,007 abstain; 42,633,186 broker non-votes. |
| Ratification of PricewaterhouseCoopers LLP | Appointment ratified for the fiscal year ending December 31, 2024. | 219,810,374 for; 966,483 against; 767,309 abstain; no broker non-votes. |
The filing contains no management guidance, business outlook, contingencies, unusual financial items, or new risk disclosures. Broker non-votes reflect shares for which nominees lacked discretionary authority and had not received voting instructions.
Important Facts to Verify
- Confirm that all four director nominees were elected and review their final terms and committee assignments.
- Assess shareholder support for executive compensation, including the approximately 28.2 million votes cast against the advisory proposal.
- Confirm the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2024.
- Review the proxy statement filed April 25, 2024 for detailed proposal disclosures and compensation information.
- Do not infer financial performance or updated guidance from this filing; it provides no such information.